AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
ProMIS Neurosciences Plunges 14.39% Amid Funding Announcement
Generated by AI AgentAinvest Pre-Market Radar
Monday, Jul 28, 2025 7:53 am ET1min read
Aime SummaryOn July 28, 2025,
experienced a significant drop of 14.39% in pre-market trading, marking a notable decline in its stock performance.ProMIS Neurosciences recently secured $12 million in financing through a combination of private placement of warrants and the exercise of existing warrants. This funding is expected to support the company's ongoing research and development efforts, particularly in the field of Alzheimer's disease treatment.
The financing round included $3 million from a private placement of warrants and an additional $9 million from the exercise of existing warrants. This strategic move is aimed at bolstering the company's financial position and accelerating its pipeline of innovative therapies.
ProMIS Neurosciences has also reported material events related to its funding assumptions, including plans for an $80 million equity raise in the second half of 2025 and a total of $1.3 billion through 2030. These financial projections indicate the company's ambitious goals and its commitment to advancing its therapeutic programs.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Getty Images (NYSE:GETY) surges 5.51% on renewed investor confidence
Jan.02 2026
Olaplex Holdings (NASDAQ: OLPX) shares plunged 7.59% on mixed analyst outlooks and shifting institutional positioning.
Jan.02 2026
The Real Brokerage shares surge 7.04% on Jan. 2 2026 driven by regulatory tailwinds and restructuring optimism
Jan.02 2026
Vanda Pharmaceuticals shares surged 25.46% on partnership and FDA Breakthrough Therapy Designation.
Jan.02 2026
Vanda Pharmaceuticals shares surge 25.46% on partnership and FDA breakthrough designation
Jan.02 2026
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments

No comments yet